Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Oramed Pharmaceuticals (ORMP) Long-Term Debt Repayments (2023 - 2025)

Oramed Pharmaceuticals' Long-Term Debt Repayments history spans 3 years, with the latest figure at -$39.7 million for Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments changed N/A year-over-year to -$39.7 million; the TTM value through Dec 2025 reached $75.4 million, changed N/A, while the annual FY2025 figure was $9.9 million, 80.07% down from the prior year.
  • Long-Term Debt Repayments reached -$39.7 million in Q4 2025 per ORMP's latest filing, down from $69.2 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $69.2 million in Q1 2025 to a low of -$39.7 million in Q4 2025.
  • Average Long-Term Debt Repayments over 3 years is $23.9 million, with a median of $25.0 million recorded in 2023.
  • The largest YoY upside for Long-Term Debt Repayments was 264.21% in 2025 against a maximum downside of 264.21% in 2025.
  • A 3-year view of Long-Term Debt Repayments shows it stood at $25.0 million in 2023, then surged by 83.31% to $45.8 million in 2024, then plummeted by 186.57% to -$39.7 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Long-Term Debt Repayments are -$39.7 million (Q4 2025), $69.2 million (Q1 2025), and $45.8 million (Q2 2024).